30 results about "Lipotoxicity" patented technology

The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

The invention belongs to the technical field of special medicinal food production, and specifically relates to prebiotics-containing formula food for special medicinal use in diabetes and a preparation method thereof. The prebiotics-containing formula food is prepared from the following components in percentage: 15 to 40 percent of yam flour, 11 to 15 percent of whey protein, 10 to 14 percent of resistant dextrin, 8 to 12 percent of walnut powder, 8 to 12 percent of xylitol, 12 to 20 percent of composite peptide powder, 5 to 9 percent of L-arabinose, 5 to 9 percent of inulin, 4 to 8 percent ofxylooliosaccaride powder 95, 0.080 to 0.1 percent of decavitamin, 0.4 to 0.45 percent of composite minerals, 2 to 6 percent of a momordica charantia extract and 1 to 5 percent of a herba gynostemmatis extract. The prebiotics-containing formula food disclosed by the invention not only is capable of effectively reducing blood glucose, but also has the functions of increasing the anti-oxidative stress ability of diabetic mice and reducing the lipotoxicity, and the function of protecting pancreatic tissues can be achieved.

The invention belongs to the medical field, and relates to an application of a pharmaceutical composition in preparing a medicament for reducing SREBP1-c, wherein the pharmaceutical composition is prepared by the following traditional Chinese medicine raw materials by weight: 540 parts of trichosanthin, 10-30 parts of radix bupleuri, 3-15 parts of citrus aurantium, 1-6 parts of raw rhubarb, 1-12 parts of pinellia tuberifera, 3-15 parts of radix scutellariae, 1-12 parts of coptis, 3-15 parts of white peony roots, and 5-20 parts of dark plums.

The present invention relates to methods of determining the levels of endogenous margaric acid before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein to fat ratio, which is useful in increasing the endogenous levels of margaric acid post-prandially and having the beneficial effects as described herein. The pet foodstuff comprises a ratio of protein to fat of 1:0.27 to 1:0.63 on a gram:gram as fed or dry matter basis. The invention also relates to methods of determining levels of lipid metabolites, such as palmitic acid, diacylglycerol (DAG), triacylglycerols (TAGs) and ceramides before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein-fat ratio, which is useful in controlling, regulating and stabilizing lipid metabolites post-prandially to prevent and/or reduce lipotoxicity in the companion animal.

Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs.

The invention belongs to a novel application of paeonol, and particularly relates to an application of paeonol in preparation of medicines for treating obesity and lipotoxic cardiomyopathy. In a model of treating mouse obesity by paeonol, through animal characterization and oil red o staining of rat primary myocardial cells, the effect of paeonol in glycolipid metabolism change and heart lipid metabolism disorder caused in a mouse obesity model fed with high fat diet is researched. The results show that paeonol can alleviate glycolipid metabolism change and heart lipid toxicity caused by obesity induced by high fat diet. Paeonol may become a potential effective treatment method for heart lipotoxicity caused by obesity.

The invention discloses an application of a rice bran active peptide in preparation of a preparation or food for preventing or treating lipid toxicity related diseases. The sequence of the rice bran active peptide is Lys-His-Asn-Arg-Gly-Asp-Glu-Phe or Lys-His-Asn-Arg-Gly-Asp-Glu. The invention further discloses a preparation method of the rice bran active peptide. Caenorhabditis elegans and C57BL/6J mice are used as model organisms, HepG2 cells are used as research objects, the effects of the rice bran active peptide on regulating lipid transport and improving dietary lipid toxicity are tested, and the result shows that the rice bran active peptide has the effects of reducing lipid toxicity and improving lipid metabolism on both the caenorhabditis elegans and the HepG2 cells. A new pharmacological mechanism of the rice bran active peptide is explained, and a new thought and means are provided for application of the rice bran active peptide in preparation of preparations or food for preventing or treating lipotoxicity related diseases.

It is found that anethol trithione (H2S donor) can significantly reduce ACC1 and FAS expression and SCD1 expression, up-regulate FADS1 and FADS2 and inhibit de novo synthesis of toxic saturated fattyacid (palmitic acid), inhibit the synthesis of oleic acid, promote the desaturation of fatty acid and adjust the proportion of n-3/n-6 polyunsaturated fatty acid under the condition of high-fat diet.Meanwhile, PAQR3 is inhibited to promote peroxidase body oxidation of lipid and degradation of LDL; in addition, the expression quantity of RTN3 can be reduced, so that the overexpression of SREPB1c is reduced, and the formation of liver cell fat droplets is reduced; the reduced expression of FATP2, FATP4, FATP5 and L-FABP can be up-regulated, which indicates that the drug enhances fatty acid uptake of hepatocytes and promotes transport of the hepatocytes; it is particularly noticed that anethol trithione can remarkably increase the expression quantity of Mitofusin 1, Mitofusin 2 and CPT1a, mitochondrial fusion is promoted, beta-oxidation of fatty acid is enhanced, and the anethol trithione is widely applied to damage of toxic fatty acid to organs such as heart, brain, liver and kidney.

A method for ameliorating, reducing, and/or preventing lipotoxicity-induced metabolic dysfunction in at least one cell is disclosed, said method comprising a step of contacting said at least one cell with a therapeutically effective amount of a synergistic anti-lipotoxicity cocktail, said cocktail comprising N-acetylcysteine, ascorbic acid, and resveratrol. Also disclosed is a method for treating at least one lipotoxicity-related metabolic disorder chosen from the group comprising (a) metabolic syndrome; (b) non-alcoholic steatohepatitis; (c) obesity; and (d) coronary heart disease, said method comprising the step of administering to a patient a therapeutically effective amount of an anti-lipotoxicity cocktail, said cocktail comprising N-acetylcysteine, ascorbic acid, and resveratrol. Finally, a composition for treating the effects of lipotoxicity, containing a synergistic combination of N-acetylcysteine, ascorbic acid, and resveratrol is disclosed.